Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax Plus Vistusertib in Relapsed SCLC and Solid Tumors
NCT03366103Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2018
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of navitoclax, vistusertib in small cell lung cancer (SCLC), solid tumor, sponsored by National Cancer Institute. Started Mar 2018; status: terminated.
02
Drugs
navitoclaxvistusertib
03
Conditions
small cell lung cancer (SCLC)solid tumor
Beyond the preview
Go deeper on NCT03366103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366103.